Sign In
Buy VTVT
$32.35
-0.330 (-1.01%)
At Close: Jul 31, 2026
vTv Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Friday, 13'th Feb 2026
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-i
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
08:00am, Monday, 02'nd Feb 2026
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million u
vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 24'th Dec 2025
vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D
Does vTv Therapeutics (VTVT) Have the Potential to Rally 25.17% as Wall Street Analysts Expect?
10:56am, Monday, 24'th Nov 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in vTv Therapeutics (VTVT). While the effectiveness of this highly sought-after metric is questionable, t
All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to Buy
01:01pm, Tuesday, 11'th Nov 2025
vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:15pm, Thursday, 06'th Nov 2025
Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issu
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
08:00am, Thursday, 09'th Oct 2025
Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials Board to offer guidance on clinical development of cadisegliatin for type 1
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
08:00am, Monday, 15'th Sep 2025
HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of i
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
04:57pm, Wednesday, 03'rd Sep 2025
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first
vTv Therapeutics to Participate in Upcoming September Investor Conferences
08:00am, Wednesday, 03'rd Sep 2025
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
08:00am, Tuesday, 02'nd Sep 2025
Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of ty
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:15pm, Tuesday, 12'th Aug 2025
• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
08:00am, Monday, 11'th Aug 2025
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-cla
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
08:00am, Thursday, 07'th Aug 2025
Topline results from CATT1 Phase 3 trial expected in second half of 2026 Topline results from CATT1 Phase 3 trial expected in second half of 2026
